Dr. Reddy's Laboratories Company Profile (NYSE:RDY)

Analyst Ratings

Consensus Ratings for Dr. Reddy's Laboratories (NYSE:RDY) (?)
Ratings Breakdown: 2 Sell Rating(s), 3 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 1.83)
Consensus Price Target: N/A

Analysts' Ratings History for Dr. Reddy's Laboratories (NYSE:RDY)
Show:
DateFirmActionRatingPrice TargetActions
7/26/2016Credit Suisse Group AGReiterated RatingNeutral -> UnderweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Goldman Sachs Group Inc.Initiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Credit Agricole SAUpgradeUnderperform -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015Deutsche Bank AGInitiated CoverageSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Citigroup Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Barclays PLCDowngradeOverweight -> Equal WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Dr. Reddy's Laboratories (NYSE:RDY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/26/2016Q117$0.00$557.00 million$479.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2016Q416$0.07$2.41 billion$567.00 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2016Q316$0.51$2.48 million$599.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q116$0.65$2.54 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q415$0.49$559.00 million$621.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2015Q315$0.53$561.00 million$610.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q115$0.54$474.00 million$486.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q414$0.52$0.47$557.00 million$580.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2014Q314$0.45$0.59$558.20 million$571.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q214$0.46$0.65$561.00 million$537.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q413$0.43$0.40$551.40 million$478.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2013$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2013Q313$0.40$505.00 million$522.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dr. Reddy's Laboratories (NYSE:RDY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Current Dividend Information for Dr. Reddy's Laboratories (NYSE:RDY)
Annual Dividend:$0.28
Dividend Yield:0.63%
Payout Ratio:15.56% (Based on Trailing 12 Months of Earnings)
13.59% (Based on Current Year Consensus EPS Estimate)
10.33% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:8.80% (3 Year Average)

Dividend History for Dr. Reddy's Laboratories (NYSE:RDY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
6/6/2016Annual$0.287/14/20167/18/20167/18/2016Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Dr. Reddy's Laboratories (NYSE:RDY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Dr. Reddy's Laboratories (NYSE:RDY)
DateHeadline
07/26/16 06:29 PMDr. Reddy's Laboratories is Now Oversold (RDY) - Forbes
07/26/16 04:49 PMDr. Reddy's Tumbles On 1Q Earnings, Venezuela Losses -
07/26/16 03:26 PMDr. Reddy's Laboratories Ltd (ADR) Is Tanking Today -- Here's Why -
07/26/16 09:27 AMCan Shares Of Dr. Reddy's Laboratories Ltd (NYSE:RDY) Hit $58.5? - Investor Newswire
07/26/16 08:26 AMDr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 -
07/26/16 05:28 AMDr. Reddy’s Q1 FY17 Financial Results - [at noodls] - 36dcd191-6477-4396-b43b-fcdb8cbb208f.pdf ••• Press ReleaseDr.Reddy's • DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. ... This is an abstract of ...
07/26/16 04:29 AMDr Reddy's Labs Q1 profit slumps 75 percent, misses estimates -
07/25/16 10:28 AMBUZZ-India's Dr. Reddy's Labs falls ahead of earnings
07/22/16 05:54 PMFirms and Funds Increasing Their Stake in Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - Engelwood Daily
07/22/16 05:54 PMDr.Reddy's Laboratories Ltd (ADR) Stock Is Crashing Now. What To Expect? - Consumer Eagle
07/21/16 08:56 AMInstitutions Increasing Their Positions in Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - Engelwood Daily
07/21/16 08:56 AMBullish Gap Up for Dr.Reddy's Laboratories Ltd (ADR) After Better Fundamentals - Consumer Eagle
07/20/16 08:55 AMLong Term Value Play: Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - TGP
07/19/16 06:14 PMBuy Dr. Reddy's Laboratories, target Rs 3700: Kunal Bothra
07/19/16 07:03 AMDr. Reddys Labs (RDY) Announces U.S. Launch of Omeprazole and Sodium Bicarbonate Caps - StreetInsider.com
07/19/16 07:03 AMAnalysts Pounding the Table on Shares of Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - TGP
07/19/16 07:03 AMIs $58.5 Price Target Attainable For Dr. Reddy's Laboratories Ltd (NYSE:RDY)? - Investor Newswire
07/18/16 11:33 AMDr Reddy’s launches Zegerid generic in US market
07/18/16 11:33 AMDr Reddy's launches anti-ulcer capsules in US
07/18/16 11:33 AMDr. Reddy's Labs launches Omeprazole and Sodium bicarbonate capsules in U.S.
07/18/16 11:33 AMDr. Reddys Labs (RDY) Announces U.S. Launch of Omeprazole and Sodium Bicarbonate Caps
07/18/16 11:19 AMWill India Benefit from the Brexit Vote? -
07/18/16 02:11 AM3:11 am Dr. Reddy's launches Omeprazole and Sodium bicarbonate capsules in the US -
07/18/16 01:43 AMDr. Reddy's Laboratories Announces the Launch of Omeprazole and Sodium bicarbonate Capsules in the U.S. Market - [Business Wire] - HYDERABAD, India & PRINCETON, N.J.--(BUSINESSWIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Omeprazole and Sodium bicarbonate capsules, ...
07/17/16 05:28 PMComplex generics, proprietary products to drive growth: Dr. Reddy’s Laboratories
07/16/16 09:20 AMDr. Reddy's Laboratories Ltd (NYSE:RDY) Updated Price Targets - FTSE News
07/14/16 06:21 PMDr Reddy’s recalls drug in the US and other top pharma news
07/14/16 09:40 AMDr. Reddy's Laboratories Ltd (RDY) Ex-Dividend Date Scheduled for July 14, 2016 - Nasdaq
07/13/16 06:27 PMDr Reddys Laboratories Ltd allots 90290 Equity Shares on exercise of ESOP
07/13/16 05:27 PMLooking For Generic Drug Stocks? Pick Up These Winners -
07/13/16 08:59 AMDr. Reddy's Laboratories Ltd Co (RDY) Investment Up in Latest Report from Vontobel Asset Management Inc - Finance Daily
07/13/16 08:59 AMStock Moving Up This Week: Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - Telanagana Press
07/12/16 06:19 PMAllotment of Equity Shares on exercise of ESOP
07/12/16 10:29 AMDr. Reddy's to Release Q1 FY17 Results on July 26, 2016 Earnings Call Slated for July 26, 6.30 PM IST / 9.00 AM EDT - Yahoo Finance
07/12/16 10:29 AMStock for the Ages: Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - Telanagana Press
07/12/16 06:55 AMDr. Reddy's to Release Q1 FY17 Results on July 26, 2016 Earnings Call Slated for July 26, 6.30 PM IST / 9.00 AM EDT - [Business Wire] - HYDERABAD, India--(BUSINESSWIRE)-- Dr. Reddy's Laboratories (NYSE: RDY | NSE: DRREDDY | BSE: 500124) will announce results for the First Quarter ended June 30, 2016 on Tuesday, July 26, 2016 after the ...
07/11/16 06:02 PMStrong Sell Calls For Dr. Reddy's Laboratories Ltd (NYSE:RDY) At 0 - Investor Newswire
07/11/16 10:44 AMStreet Analyst Viewing Shares in Positive Light: Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - Telanagana Press
07/11/16 10:44 AMDr. Reddy's Laboratories Ltd (NYSE:RDY) Broker Price Targets For The Coming Week - Fiscal Standard
07/10/16 10:07 AMSLSWC MA approves Rs 543.26 crore of industrial projects
07/09/16 05:28 PMDr. Reddy's Laboratories Ltd (NYSE:RDY) Current Analyst Ratings - Fiscal Standard
07/08/16 02:21 AMPromius Pharma Launches New Corporate Brand Identity - [at noodls] - Microsoft Word - .docx Press Release Contact: INVESTOR RELATIONS Ashish Girotra [email protected] (Ph: +1 6093756145) MEDIA RELATIONS Lori McCreary [email protected] (Ph: +1 6093752995) Princeton, ...
07/07/16 08:53 AMDr Reddy’s and Lupin recall drug in the US
07/06/16 10:44 AMDr. Reddy's: Regulatory And Emerging Market Woes Provide Excellent Risk-Reward
07/05/16 05:49 PMBroker Outlook For The Week Ahead Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Fiscal Standard
07/04/16 05:14 PMDr. Reddy's Laboratories Ltd (NYSE:RDY) Expected to Reach Highs Of $45 - Investor Newswire
07/03/16 10:15 AMDr Reddy’s set to complete remediation work, to seek USFDA re-inspection soon
06/30/16 08:54 AMNew Broker Ratings For Dr. Reddy's Laboratories Ltd (NYSE:RDY) - FTSE News
06/29/16 12:04 PMDR REDDYS LABORATORIES LTD Financials -
06/27/16 06:02 PMStrong Sell Calls Recommendations For Dr. Reddy's Laboratories Ltd (NYSE:RDY) At 0 - Investor Newswire

Social

About Dr. Reddy's Laboratories

Dr. ReddyDr. Reddy's Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter (OTC) finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients (API) and intermediates. Proprietary Products segment consists of its differentiated formulations business, its new chemical entities (NCEs) business and its dermatology focused specialty business. The Company's OTC brands include Doan's, Bufferin, Nupercainal Ointment, Cruex Nail Gel, Comtrex and Myoflex.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: RDY
  • CUSIP:
Key Metrics:
  • Previous Close: $44.11
  • 50 Day Moving Average: $49.83
  • 200 Day Moving Average: $46.22
  • P/E Ratio: 25.32
  • P/E Growth: 2.94
  • Market Cap: $7.53B
  • Beta: 0.9
  • Current Year EPS Consensus Estimate: $2.06 EPS
  • Next Year EPS Consensus Estimate: $2.71 EPS
Additional Links:
Dr. Reddy's Laboratories (NYSE:RDY) Chart for Tuesday, July, 26, 2016